A critical appraisal of tools available for monitoring epigenetic changes in clinical samples from patients with myeloid malignancies

Kirsten Gronbaek, Carsten Muller-Tidow, Giovanni Perini, Soren Lehmann, Marianne Bach Treppendahl, Ken Mills, Christoph Plass, Brigitte Schlegelberger

Research output: Contribution to journalArticlepeer-review

15 Citations (Scopus)
148 Downloads (Pure)

Abstract

Research over the past decade has confirmed that epigenetic alterations act in concert with genetic lesions to deregulate gene expression in acute myeloid leukemia and myelodysplastic syndromes. In addition, we now have the capability to pharmaceutically target epigenetic modifications, and there is an urgent need forearly validation of the efficacy of the drugs. Also, an improved understanding of the functionality of epigenetic modifications may further pave the road towards an individualized therapy. Here, we provide the pros and cons of the currently most feasible methods used for characterizing the methylome in clinical samples, and give a brief introduction to novel approaches to sequencing that may revolutionize our abilities to characterize the genomes and epigenomes in acute myeloid leukemia and myelodysplastic syndrome patients.
Original languageEnglish
Pages (from-to)1380-1388
Number of pages9
JournalHAEMATOLOGICA
Volume97
Issue number9
DOIs
Publication statusPublished - 01 Sep 2012

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'A critical appraisal of tools available for monitoring epigenetic changes in clinical samples from patients with myeloid malignancies'. Together they form a unique fingerprint.

Cite this